Financial issues constraining the use of pancreata recovered for islet transplantation

A white paper

J. F. Markmann, D. B. Kaufman, Camillo Ricordi, P. M. Schwab, P. G. Stock

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Islet transplantation is a very promising therapy for select patients with type 1 diabetes. Continued clinical investigation is required to define the long-term safety and efficacy outcomes before the procedure will be accepted as a standard of care even for those with the most severe manifestations of diabetes. Threatening successful accomplishment of these and other innovative studies designed to advance the field are the complex financial cost accounting issues that pose undue burden on organ procurement organizations and transplant centers trying to manage the costs of the pancreata from deceased donors needed to isolate islets. Compounding the problem is the recent ruling by CMS regarding 'intent to transplant' (CMS-1543-R Dec. 21, 2006: Allocation of Donor Acquisition Costs Incurred by Organ Procurement Organizations) that does not account for the clinical need to complete the manufacturing process for islets before suitability and transplant intent of the pancreata involved can be determined. We provide a consensus document supported by a diverse group of stakeholders in islet transplantation to suggest actions to address this problem.

Original languageEnglish
Pages (from-to)1588-1592
Number of pages5
JournalAmerican Journal of Transplantation
Volume8
Issue number8
DOIs
StatePublished - Aug 1 2008

Fingerprint

Islets of Langerhans Transplantation
Pancreas
Tissue and Organ Procurement
Transplants
Costs and Cost Analysis
Tissue Donors
Organizations
Standard of Care
Type 1 Diabetes Mellitus
Safety
Therapeutics

Keywords

  • Organ acquisition costs
  • Pancreata
  • Pancreatic islets
  • Transplantation

ASJC Scopus subject areas

  • Immunology

Cite this

Financial issues constraining the use of pancreata recovered for islet transplantation : A white paper. / Markmann, J. F.; Kaufman, D. B.; Ricordi, Camillo; Schwab, P. M.; Stock, P. G.

In: American Journal of Transplantation, Vol. 8, No. 8, 01.08.2008, p. 1588-1592.

Research output: Contribution to journalArticle

Markmann, J. F. ; Kaufman, D. B. ; Ricordi, Camillo ; Schwab, P. M. ; Stock, P. G. / Financial issues constraining the use of pancreata recovered for islet transplantation : A white paper. In: American Journal of Transplantation. 2008 ; Vol. 8, No. 8. pp. 1588-1592.
@article{e5b6533551c24eb995c3c632b841fec3,
title = "Financial issues constraining the use of pancreata recovered for islet transplantation: A white paper",
abstract = "Islet transplantation is a very promising therapy for select patients with type 1 diabetes. Continued clinical investigation is required to define the long-term safety and efficacy outcomes before the procedure will be accepted as a standard of care even for those with the most severe manifestations of diabetes. Threatening successful accomplishment of these and other innovative studies designed to advance the field are the complex financial cost accounting issues that pose undue burden on organ procurement organizations and transplant centers trying to manage the costs of the pancreata from deceased donors needed to isolate islets. Compounding the problem is the recent ruling by CMS regarding 'intent to transplant' (CMS-1543-R Dec. 21, 2006: Allocation of Donor Acquisition Costs Incurred by Organ Procurement Organizations) that does not account for the clinical need to complete the manufacturing process for islets before suitability and transplant intent of the pancreata involved can be determined. We provide a consensus document supported by a diverse group of stakeholders in islet transplantation to suggest actions to address this problem.",
keywords = "Organ acquisition costs, Pancreata, Pancreatic islets, Transplantation",
author = "Markmann, {J. F.} and Kaufman, {D. B.} and Camillo Ricordi and Schwab, {P. M.} and Stock, {P. G.}",
year = "2008",
month = "8",
day = "1",
doi = "10.1111/j.1600-6143.2008.02305.x",
language = "English",
volume = "8",
pages = "1588--1592",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Financial issues constraining the use of pancreata recovered for islet transplantation

T2 - A white paper

AU - Markmann, J. F.

AU - Kaufman, D. B.

AU - Ricordi, Camillo

AU - Schwab, P. M.

AU - Stock, P. G.

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Islet transplantation is a very promising therapy for select patients with type 1 diabetes. Continued clinical investigation is required to define the long-term safety and efficacy outcomes before the procedure will be accepted as a standard of care even for those with the most severe manifestations of diabetes. Threatening successful accomplishment of these and other innovative studies designed to advance the field are the complex financial cost accounting issues that pose undue burden on organ procurement organizations and transplant centers trying to manage the costs of the pancreata from deceased donors needed to isolate islets. Compounding the problem is the recent ruling by CMS regarding 'intent to transplant' (CMS-1543-R Dec. 21, 2006: Allocation of Donor Acquisition Costs Incurred by Organ Procurement Organizations) that does not account for the clinical need to complete the manufacturing process for islets before suitability and transplant intent of the pancreata involved can be determined. We provide a consensus document supported by a diverse group of stakeholders in islet transplantation to suggest actions to address this problem.

AB - Islet transplantation is a very promising therapy for select patients with type 1 diabetes. Continued clinical investigation is required to define the long-term safety and efficacy outcomes before the procedure will be accepted as a standard of care even for those with the most severe manifestations of diabetes. Threatening successful accomplishment of these and other innovative studies designed to advance the field are the complex financial cost accounting issues that pose undue burden on organ procurement organizations and transplant centers trying to manage the costs of the pancreata from deceased donors needed to isolate islets. Compounding the problem is the recent ruling by CMS regarding 'intent to transplant' (CMS-1543-R Dec. 21, 2006: Allocation of Donor Acquisition Costs Incurred by Organ Procurement Organizations) that does not account for the clinical need to complete the manufacturing process for islets before suitability and transplant intent of the pancreata involved can be determined. We provide a consensus document supported by a diverse group of stakeholders in islet transplantation to suggest actions to address this problem.

KW - Organ acquisition costs

KW - Pancreata

KW - Pancreatic islets

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=48349122352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48349122352&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2008.02305.x

DO - 10.1111/j.1600-6143.2008.02305.x

M3 - Article

VL - 8

SP - 1588

EP - 1592

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 8

ER -